Ticlopidine

Ticlopidine

File:Ticlopidine.svg
Systematic (IUPAC) name
5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
Clinical data
Pregnancy category	AU: B1 US: C (Risk not ruled out)
Routes of administration	Oral
Pharmacokinetic data
Bioavailability	>80%
Protein binding	98%
Metabolism	Hepatic
Biological half-life	12 hours (single dose) 4 to 5 days (after repeated dosing)
Excretion	Renal and fecal
Identifiers
CAS Number	55142-85-3
ATC code	B01AC05 (WHO)
PubChem	CID 5472
DrugBank	APRD01257
Chemical data
Formula	C14H14ClNS
Molar mass	263.786 g/mol[[]]
(verify)

Ticlopidine (trade name Ticlid) is an antiplatelet drug in the thienopyridine family. Like clopidogrel, it is an adenosine diphosphate (ADP) receptor inhibitor. It is used in patients in whom aspirin is not tolerated, or in whom dual antiplatelet therapy is desirable. Because it has been reported to increase the risk of thrombotic thrombocytopenic purpura (TTP) and neutropenia, its use has largely been supplanted by the newer drug, clopidogrel, which is felt to have a much lower hematologic risk. The usual dose is 250 mg twice daily by the oral route.

Action

• Inhibits platelet aggregation by altering the function of platelet membranes by blocking ADP receptors. This prevents the conformational change of glycoprotein IIb/IIIa which allows platelet binding to fibrinogen.
• Prolongs bleeding time.
• Decreased incidence of stroke in high-risk patients.

Contraindications

• Hypersensitivity
• Bleeding disorders
• Active bleeding
• Severe liver disease

Precautions

• Risk of bleeding (trauma, surgery, history of peptic ulcer disease)
• Renal or hepatic impairment
• Geriatric patients (increased sensitivity)
• Pregnancy, lactation, or children under 18
• Neutropenia
• Thrombotic thrombocytopenic purpura

de:Ticlopidin